Shares of Delcath Systems Inc. (DCTH) touched a new 52-week high of $16.97 last week, and that reflects a gain of over 100% in less than 6 months.
This interventional oncology company, focused on the treatment of primary and metastatic cancers of the liver, markets HEPZATO KIT, a drug/device combination product, which is comprised of the chemotherapeutic drug Melphalan and Delcath's proprietary Hepatic Delivery System (HDS).
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.